MGTA Magenta Therapeutics Inc.

9.39
+0.72  (+8%)
Previous Close 8.67
Open 8.85
Price To Book 1.95
Market Cap 311292951
Shares 33,151,539
Volume 73,054
Short Ratio
Av. Daily Volume 117,994

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 1H 2019.
MGTA-456
Sickle cell disease
Phase 2 data noted all patients met primary endpoint.
MGTA-456
Inherited Metabolic Disorders (IMD)
Phase 2 data due at ASH 2019.
MGTA-456
Acute Lymphoblastic Leukemia
Phase 1 initial data due at ASH 2019.
MGTA-145
Healthy volunteers

Latest News

  1. Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
  2. Magenta Therapeutics to Present at Guggenheim Healthcare Investor Conference
  3. Magenta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019
  4. Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit
  5. Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders
  6. Magenta Therapeutics Presents New Preclinical Data on MGTA-145 Stem Cell Mobilization Product Candidate
  7. Magenta Therapeutics to Host Webcast of Investor and Analyst Event During ASH
  8. Magenta Therapeutics Appoints Jason Ryan as Chief Operating and Financial Officer
  9. Magenta Therapeutics Reports Recent Operational Progress and Third Quarter 2018 Financial Results
  10. Magenta Therapeutics Announces Acceptance of Nine Abstracts Covering Clinical and Preclinical Data at ASH, Representing Progress across the Portfolio of Conditioning, Stem Cell Mobilization and Expansion Programs
  11. Magenta Therapeutics Added to Russell 2000 and 3000 Indexes
  12. Magenta Therapeutics Reports Recent Operational Progress and Second Quarter 2018 Financial Results
  13. Magenta Therapeutics to Present at Wedbush PacGrow Healthcare Conference
  14. Breakfast Technical Briefing on Neptune Technologies & Bioressources and Three Other Additional Biotech Stocks
  15. Wedbush Bets On Magenta Therapeutics, Projects Rewards If Stem Cell Technology Successful
  16. Magenta Therapeutics Announces Closing of Initial Public Offering